Mylan Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Mylan Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#191 of 15,742 sponsors by registered trial count).
Mylan Pharmaceuticals: 146 sponsored US clinical trials, 1 recruiting.
Mylan Pharmaceuticals sponsors 146 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 143 completed. 3 of these trials are in Phase 3-4 (later-stage) and 143 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 35 trials.
Top-decile sponsor footprint
Mylan Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#191 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
143 of 145 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (98.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
146 total, page 1 of 3
Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
NCT06672016
Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)
NCT03610646
A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis
NCT02195986
Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)
NCT00978055
Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg
NCT01183676
Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg
NCT01184391
Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg
NCT00985660
Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers
NCT00979537
Fasting Study of Levothyroxine Sodium Tablets 300 mcg to Synthroid® Tablets 300 mcg
NCT00648882
Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets 40 mg
NCT00730197
Fed Study of Balsalazide Disodium Capsules 750 mg and Colazal® Capsules 750 mg
NCT00649480
Food Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg
NCT00650403
Fasting Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg
NCT00648193
Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg
NCT01020214
Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg
NCT01019590
Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System
NCT00650117
Study of the Effect of Clinical Procedures on Drug Delivery of Mylan Fentanyl Transdermal System 25 µg/hr and Duragesic® 25 µg/hr
NCT00648414
Fed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg
NCT00648297
Fasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg
NCT00647660
Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System With Askina Derm Overlay
NCT00647686
Fasting Study of Doxycycline Monohydrate Tablets 150 mg and Adoxa Tablets 150 mg
NCT00647959
Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg
NCT00648050
Fasting Study of Fluoxetine Capsules 40 mg and Prozac Pulvules 40 mg
NCT00649636
Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg
NCT00647673
Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg
NCT00649805
Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg
NCT00649272
Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg
NCT00648401
Fed Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg
NCT00648219
Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg
NCT00649623
Fasting Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg
NCT00649740
Food Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg
NCT00648154
Fed Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg
NCT00648934
Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg
NCT00648063
Fasting Study of Ciprofloxacin Extended-Release Tablets 500 mg and Cipro® XR Tablets 500 mg
NCT00649155
Applesauce Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg
NCT00649467
Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System
NCT00647842
Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg
NCT00649662
Food Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg
NCT00650351
Steady-State Study of Extended Phenytoin Sodium Capsules 100 mg and Dilantin® Kapseals® 100 mg
NCT00647621
Fasting Study of Hydrochlorothiazide Tablets 50 mg to Hydrochlorothiazide Tablets 50 mg
NCT00649324
Fed Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg
NCT00649987
Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg
NCT00647816
Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg
NCT00647608
Fasting Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg
NCT00649779
Fed Study of Valacyclovir Hydrochloride Tablets 1000 mg and Valtrex® Tablets 1000 mg
NCT00650494
Fasting Study of Levothyroxine Sodium Tablets 300 μg to Levothroid® Tablets 300 μg
NCT00648700
Fasting Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mg
NCT00649363
Food Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mg
NCT00648804
Food Study of Doxycycline Monohydrate Tablets 100 mg and Adoxa Tablets 100 mg
NCT00648180
Fasting Study of Doxycycline Monohydrate Tablets 100 mg and Adoxa Tablets 100 mg
NCT00649571
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 143 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the Mylan Pharmaceuticals pipeline
1 recruiting of 146 indexed (1% open); 143 completed (98%).
Phase mix: 3 late (III/IV) vs 143 early (I/II) (early-phase heavy).
Top condition: Healthy (35 trials), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Mylan Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 146 registered trials and 1% open enrollment, not the therapeutic-area sidebar.
Mylan Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 146 trials (± recruiting share)
- HealthPartners Institute · 146 trials · 8% recruiting
- SCRI Development Innovations · 146 trials · 3% recruiting
- Forest Laboratories · 145 trials · 0% recruiting
- National Institute of Environmental Health Sciences (NIEHS) · 145 trials · 10% recruiting
Sponsors near 1% open enrollment (± trial volume)
- Johnson & Johnson Vision Care · 1% recruiting · 142 trials
- Gynecologic Oncology Group · 1% recruiting · 154 trials
- Shire · 0% recruiting · 245 trials
- Abbott Nutrition · 1% recruiting · 89 trials
Related
What to do with this Mylan Pharmaceuticals page
146 registered trials is a research-attention snapshot, not an endorsement of Mylan Pharmaceuticals or any single study.
- 1 of Mylan Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Mylan Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Mylan Pharmaceuticals pipeline card: 146 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.